The Claim
In obese male non-human primates, dual blockade of GDF8 and activin A during GLP-1 therapy is associated with greater improvements in glycated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) compared to GLP-1 therapy alone.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese male primates, combining a treatment that blocks two specific proteins (GDF8 and activin A) with GLP-1 therapy leads to larger improvements in blood sugar control and cholesterol levels than GLP-1 therapy by itself.
See the scientific wording
In obese male non-human primates, dual GDF8 and activin A blockade during GLP-1 therapy is associated with greater improvements in glycated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) compared to GLP-1 therapy alone, suggesting enhanced metabolic benefits.
What the research says
1 studyWhen obese monkeys got a weight-loss drug (GLP-1) plus a treatment that stops muscle loss, they lost more fat and stayed healthier overall — suggesting their blood sugar and cholesterol improved too.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.